Admassie, E and Chalmers, L and Bereznicki, LR, Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study, European Journal of Clinical Pharmacology, 73, (12) pp. 1681-1689. ISSN 0031-6970 (2017) [Refereed Article]
Copyright Springer-Verlag GmbH Germany 2017
Purpose: Limited data are available from the Australian setting regarding bleeding in patients with atrial fibrillation (AF) receiving antithrombotic therapy. We aimed to investigate the incidence of hospital admissions due to bleeding and factors associated with bleeding in patients with AF who received antithrombotic therapy.
Methods: A retrospective cohort study was conducted involving all patients with AF admitted to the Royal Hobart Hospital, Tasmania, Australia, between January 2011 and July 2015. Bleeding rates were calculated per 100 patientyears (PY) of follow-up, and multivariable modelling was used to identify predictors of bleeding.
Results: Of 2202 patients receiving antithrombotic therapy, 113 presented to the hospital with a major or minor bleeding event. These patients were older, had higher stroke and bleeding risk scores and were more often treated with warfarin and multiple antithrombotic therapies than patients who did not experience bleeding. The combined incidence of major and minor bleeding was significantly higher in warfarin- versus direct-acting oral anticoagulants (DOAC)- and antiplatelet-treated patients (4.1 vs 3.0 vs 1.2 per 100 PY, respectively; p = 0.002). Similarly, the rate of major bleeding was higher in patients who received warfarin than in the DOAC and antiplatelet cohorts (2.4 vs 0.4 vs 0.6 per 100 PY, respectively; p = 0.001). In multivariate analysis, increasing age, prior bleeding, warfarin and multiple antithrombotic therapies were independently associated with bleeding.
Conclusion: The overall rate of bleeding in this cohort was low relative to similar observational studies. The rate of major bleeding was higher in patients prescribed warfarin compared to DOACs, with a similar rate of major bleeding for DOACs and antiplatelet agents. Our findings suggest potential to strategies to reduce bleeding include using DOACs in preference to warfarin, and avoiding multiple antithrombotic therapies in patients with AF.
|Item Type:||Refereed Article|
|Keywords:||AF, bleeding, elderly, atrial fibrillation, anticoagulant, DOACs, bleeding|
|Research Division:||Medical and Health Sciences|
|Research Group:||Pharmacology and Pharmaceutical Sciences|
|Research Field:||Clinical Pharmacy and Pharmacy Practice|
|Objective Group:||Other Health|
|Objective Field:||Health not elsewhere classified|
|UTAS Author:||Admassie, E (Mr Endalkachew Alamneh)|
|UTAS Author:||Chalmers, L (Dr Leanne Chalmers)|
|UTAS Author:||Bereznicki, LR (Professor Luke Bereznicki)|
|Web of Science® Times Cited:||1|
|Downloads:||6 View Download Statistics|
Repository Staff Only: item control page